Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Classical hematology 1CNS 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Burkitt Lymphoma 4Ovarian Neoplasms 3Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 2Lung Neoplasms 2Head and Neck Neoplasms 2Xerostomia 1Thyroid Carcinoma, Anaplastic 1Thrombocytopenia 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Recurrence 1Prostatic Neoplasms 1Previously Treated Non Small Cell Lung Cancer 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Pain 1Osteosarcoma 1Neutropenia 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Multiple Myeloma 1

Interventions

Filgrastim 3Carboplatin 3sodium thiosulfate 2etoposide phosphate 2Radiotherapy 2Cyclophosphamide 2Amifostine 2pegfilgrastim 1glucarpidase 1Triptorelin Pamoate 1Rituximab 1Peripheral Blood Stem Cell Transplantation 1Paclitaxel 1Melphalan 1Mannitol 1Granulocyte Colony-Stimulating Factor 1Etoposide 1Cytarabine 1Cisplatin 1Celecoxib 1Capecitabine 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Drug-Related Side Effects and Adverse Reactions × pegfilgrastim × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡